Table 1.
Recipient-, donor-, and transplant-associated characteristics of patients with a diagnosis of TG
| Characteristic | Patients with TG (n=385) | |
|---|---|---|
| n | ||
| Recipient characteristics | ||
| Age (yr), mean (SD) | 385 | 43.95 (15.69) |
| Male, n (%) | 385 | 226 (58.70) |
| ESRD causes, n (%) | 385 | |
| GN | 162 (42.08) | |
| Diabetes | 38 (9.87) | |
| Vascular | 20 (5.19) | |
| Tubulo-interstitial | 84 (21.82) | |
| Other | 9 (2.34) | |
| Unknown | 72 (18.70) | |
| GN ESRD causes, n (%) | 162 | |
| MPGN | 27 (16.67) | |
| TMA | 12 (7.41) | |
| IgA nephropathy | 56 (34.57) | |
| Lupus | 13 (8.02) | |
| Membranous nephropathy | 7 (4.32) | |
| Alport | 8 (4.94) | |
| Amyloidosis | 1 (0.62) | |
| FSGS | 20 (12.35) | |
| Crescent glomerulopathy | 9 (5.56) | |
| Unspecified | 9 (5.56) | |
| Positive serology at the time of transplant, n (%) | ||
| HCV | 385 | 35 (9.09) |
| HBV | 365 | 27 (7.40) |
| HIV | 385 | 2 (0.52) |
| CMV | 381 | 238 (62.47) |
| Donor characteristics | ||
| Age (yr), mean (SD) | 368 | 47.40 (16.97) |
| Male, n (%) | 376 | 189 (50.27) |
| Creatinine (μmol/L), mean (SD) | 357 | 81.04 (40.87) |
| Deceased donor, n (%) | 385 | 283 (73.51) |
| Double transplantation, n (%) | 385 | 19 (4.94) |
| Positive serology, n (%) | ||
| Hepatitis C virus | 353 | 4 (1.13) |
| Hepatitis B virus | 355 | 10 (2.82) |
| HIV | 385 | 0 |
| CMV | 379 | 210 (55.41) |
| Transplant baseline characteristics | ||
| Prior kidney transplant, n (%) | 385 | 78 (20.26) |
| Cold ischemia time (h), mean (SD) | 381 | 15.54 (10.16) |
| Delayed graft function, n (%)a | 385 | 107 (27.79) |
| HLA A/B/DR mismatch, mean (SD), number | 385 | 3.47 (1.46) |
| Donor-specific anti-HLA antibodies on d 0, n (%) | 385 | 64 (16.62) |
| Circulating anti-HLA DSA MFI, median (IQR) | 2625 (868–10,155) | |
HCV, hepatitis C virus; HBV, hepatitis B virus; CMV, Cytomegalovirus; HLA, human leukocyte antigen; DSA, donor-specific antibodies.
a
Delayed graft function was defined as the use of dialysis in the first postoperative wk.